

Supplementary Materials: Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer




Figure S1. Prefoldin expression was semi-quantitatively scored by two independent pathologists on a range of 0 to 3+. Scale bar: 50 μ m.




Figure S2. Kaplan–Meier curves of all 58 patients for disease-free survival (DFS) according to PFDN expression. Patients with PFDN1 (A), 3 (B) and 5 (C) overexpression had lower DFS.




Figure S3. Kaplan–Meier curves of all 58 patients for (A) disease-free survival (DFS) and (B) distant metastasis-free survival (DMFS) when combining all overexpressed PFDNs. Patients with PFDN1 and 3 overexpression had lower (A) DFS and (B) DMFS.

Table S1. Univariate analyses of the associations between patient characteristics and prefoldin (PFDN) protein expression levels and the outcome.

Parameter	Overall Survival			Disease-Free Survival			Local Recurrence			Distant Metastases		<i>p</i> -value
	HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value	HR	95% CI	
Gender												
Male (Ref)	1			1			1			1		
Female	0.47	0.14–1.56	0.221	0.84	0.29–2.40	0.751	0.50	0.11–2.18	0.360	0.98	0.29–3.33	0.985
Age, years												
≤67 (Ref)	1			1			1			1		
>67	0.83	0.43–1.59	0.584	0.80	0.59–1.41	0.695	0.71	0.30–1.70	0.451	0.70	0.31–1.60	0.410
COPD												
No (Ref)	1			1			1			1		
Yes	0.99	0.52–1.89	0.984	0.58	0.28–1.21	0.149	1.13	0.47–2.72	0.773	0.49	0.20–1.20	0.122
Cardiovascular disease												
No (Ref)	1			1			1			1		
Yes	1.89	0.92–3.87	0.079	1.37	0.62–3.062	0.430	1.31	0.47–3.59	0.600	2.28	0.96–5.40	0.059
Smoking status												
Former/Never (Ref)	1			1			1			1		
Current	1.36	0.72–2.58	0.340	0.70	0.35–1.42	0.336	0.69	0.28–1.67	0.419	1.04	0.46–2.33	0.917
Alcohol												
No (Ref)	1			1			1			1		
Yes	1.14	0.59–2.21	0.682	0.97	0.48–1.94	0.934	0.70	0.29–1.70	0.437	1.34	0.59–3.05	0.476
KPS												
≥80 (Ref)	1			1			1			1		
<80	1.63	0.80–3.322	0.179	0.86	0.35–2.10	0.747	0.88	0.29–2.65	0.820	0.81	0.27–2.40	0.713
Weight												
<78 (Ref)	1			1			1			1		
≥78	0.60	0.31–1.16	0.133	0.46	0.22–0.94	0.034	0.63	0.26–1.52	0.307	0.27	0.10–0.69	0.006
Body Surface												
<188 (Ref)	1			1			1			1		
≥188	0.41	0.21–0.81	0.010	0.46	0.22–0.93	0.033	0.85	0.35–2.04	0.726	0.22	0.08–0.56	0.002
Tumor Histology												
Adeno (Ref)	1			1			1			1		
Squamous cell	0.92	0.48–1.78	0.821	0.76	0.38–1.52	0.445	1.60	0.64–4.02	0.314	0.49	0.22–1.12	0.092

Clinical stage													
I - II (Ref)	1			1			1			1			
III - IV	2.04	0.94–4.42	0.069	2.12	0.94–4.74	0.067	1.28	0.51–3.23	0.596	3.94	1.17–13.29	0.027	
Surgery													
No (Ref)	1			1			1			1			
Yes	0.42	0.17–1.04	0.061	0.51	0.17–1.46	0.210	0.71	0.16–3.09	0.651	0.34	0.11–1.00	0.051	
Chemotherapy													
No (Ref)	1			1			1			1			
Yes	1.55	0.75–3.18	0.231	1.75	0.78–3.89	0.170	1.30	0.50–3.37	0.590	4.59	1.34–15.75	0.015	
Concomitant chemotherapy													
No (Ref)	1			1			1			1			
Yes	3.31	1.38–7.93	0.007	2.51	0.94–6.68	0.066	2.16	0.61–7.70	0.231	3.88	1.38–10.91	0.010	
Radiotherapy													
No (Ref)	1			1			1			1			
Yes	1.84	0.92–3.66	0.082	1.59	0.79–3.2	0.189	1.21	0.49–2.96	0.667	3.39	1.44–7.96	0.015	
PFDN1*													
0/+ /++ (Ref)	1			1			1			1			
+++	2.86	1.47–5.56	0.002	2.53	1.24–5.15	0.010	1.68	0.67–4.23	0.266	2.94	1.28–6.73	0.011	
PFDN3*													
0/+ /++ (Ref)	1			1			1			1			
+++	2.30	1.17–4.50	0.015	2.09	1.02–4.27	0.042	1.50	0.62–3.63	0.362	2.50	1.06–5.88	0.036	
PFDN5*													
0/+ /++ (Ref)	1			1			1			1			
+++	2.94	1.50–5.76	0.002	2.00	0.98–4.06	0.055	1.74	0.70–4.32	0.227	1.94	0.85–4.42	0.112	

Abbreviations: HR. hazard ratio; COPD. Chronic obstructive pulmonary disease; KPS. Karnofsky performance status; PFDN. Prefoldin. * (+), weak expression; 2 (++) , strong expression, and 3 (+++), very strong expression

Table S2. Multivariate analyses of the associations between patient characteristics and PFDN expression and outcome.

Parameter	Overall Survival			Disease Free Survival			Distant Metastases		
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Body Surface									
<188 (Ref)							1		
≥188							0.27	0.10-0.72	0.009
Concomitant Chemotherapy									
No (Ref)	1								
Yes	3.76	1.55-9.11	0.003						
Radiotherapy									
No (Ref)							1		
Yes							3.44	1.42-8.34	0.006
PFDN1									
0/+ /++ (Ref)				1			1		
+++				2.53	1.24-5.15	0.010	2.32	0.98-5.45	0.053
PFDN5									
0/+ /++ (Ref)	1								
+++	3.13	1.59-6.15	0.001						

Abbreviations: HR, hazard ratio; PFDN, prefoldin. * (+), weak expression; 2 (++) , strong expression, and 3 (+++), very strong expression